Pfizer Corporation

Biontech Se

Kena Anne Swanson

Mark Edward Ruppen

Philip R Dormitzer

Avvari Krishna Prasad

Ye Che

Xin Xu

Ping Cai

Xiayang Qiu

Srinivas Kodali

Alexey Vyacheslavovich Gribenko

Luke David Handke

Xi Song

KariAnn Sweeney Efferen

Kristin Rachael Tompkins

Lorna Del Pilar Nunez

Ugur Sahin

Alexander Muik

Hui Cai

Qi Yang

Kayvon Modjarrad

Asaf Poran

Philip Ralph Dormitzer

Kariann Sweeney Efferen

The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.

RSV F protein mutants

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

Coronavirus vaccine

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-COV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-COV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses.

Growing community of inventors

Pearl River, NY, United States of America

Kena Anne Swanson